A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

Clinical trial NCT01707069 · COMPLETED

Trial details

NCT number: NCT01707069
Sponsor: Immunomic Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Allergic Rhinoconjunctivitis

Start date: 2012-10-01
Primary completion: 2013-05-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.